Literature DB >> 23835028

Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo.

Seyed Hamid Jalalian1, Seyed Mohammad Taghdisi, Nasim Shahidi Hamedani, Seyedeh Alia Moosavian Kalat, Parirokh Lavaee, Majid Zandkarimi, Narjes Ghows, Mahmoud Reza Jaafari, Saeed Naghibi, Noor Mohammad Danesh, Mohammad Ramezani, Khalil Abnous.   

Abstract

Every year a large number of new cases of colorectal cancer are diagnosed in the world. Application of Epirubicin (Epi) in treatment of cancer has been limited due to its cardiotoxicity. Specific delivery of chemotherapy drugs is an important factor in reducing the side effects of drugs used in chemotherapy. Enhanced permeability, retention effect and magnetic resonance (MR) traceability of super paramagnetic iron oxide nanoparticles (SPION) make them a great candidate in cancer therapy and imaging. In this study, Epirubicin-5TR1 aptamer-SPION tertiary complex was evaluated for the imaging and treatment of murine colon carcinoma cells (C26 cells, target). For cytotoxic studies (MTT assay), C26 and CHO-K1 (Chinese hamster ovary cells, nontarget) cells were treated with either Epi or Epi-Apt-SPION tertiary complex. Internalization was evaluated by flow cytometry. Finally, Apt-SPION bioconjugate was used for imaging of cancer in vivo. Flow cytometric analysis showed that the tertiary complex was internalized effectively to C26 cells, but not to CHO-K1 cells. Cytotoxicity of Epi-Apt-SPION tertiary complex also confirmed internalization data. The complex was less cytotoxic in CHO-K1 cells when compared to Epi alone. No significant change in viability between Epi- and complex-treated C26 cells was observed. Magnetic resonance imaging (MRI) indicated a high level of accumulation of the nano-magnets within the tumor site. In conclusion Epi-Apt-SPION tertiary complex is introduced as an effective system for targeted delivery of Epi to C26 cells. Moreover this complex could efficiently detect tumors when analyzed by MRI and inhibit tumor growth in vivo.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aptamer; Colon cancer; Epirubicin; MRI; SPION

Mesh:

Substances:

Year:  2013        PMID: 23835028     DOI: 10.1016/j.ejps.2013.06.015

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  26 in total

1.  Enhanced antitumor activity and attenuated cardiotoxicity of Epirubicin combined with Paeonol against breast cancer.

Authors:  Jing Wu; Xia Xue; Bin Zhang; Hongmei Cao; Feng Kong; Wen Jiang; Juan Li; Deqing Sun; Ruichen Guo
Journal:  Tumour Biol       Date:  2016-06-07

2.  Identification of epithelial ovarian tumor-specific aptamers.

Authors:  Gregory Benedetto; Timothy J Hamp; Peter J Wesselman; Christine Richardson
Journal:  Nucleic Acid Ther       Date:  2015-04-20       Impact factor: 5.486

Review 3.  Applications of aptamers in targeted imaging: state of the art.

Authors:  Casey A Dougherty; Weibo Cai; Hao Hong
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

Review 4.  Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.

Authors:  Gregory Benedetto; C Greer Vestal; Christine Richardson
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

Review 5.  Present Scenario of Bioconjugates in Cancer Therapy: A Review.

Authors:  Aishani Wadhawan; Mary Chatterjee; Gurpal Singh
Journal:  Int J Mol Sci       Date:  2019-10-23       Impact factor: 5.923

6.  Application of aptamers in diagnostics, drug-delivery and imaging.

Authors:  Chetan Chandola; Sheetal Kalme; Marco G Casteleijn; Arto Urtti; Muniasamy Neerathilingam
Journal:  J Biosci       Date:  2016-09       Impact factor: 2.795

7.  Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells.

Authors:  Katarzyna Niemirowicz; Izabela Prokop; Agnieszka Z Wilczewska; Urszula Wnorowska; Ewelina Piktel; Marzena Wątek; Paul B Savage; Robert Bucki
Journal:  Int J Nanomedicine       Date:  2015-06-04

8.  Superparamagnetic iron oxide nanoparticles conjugated with epidermal growth factor (SPION-EGF) for targeting brain tumors.

Authors:  Maxim A Shevtsov; Boris P Nikolaev; Ludmila Y Yakovleva; Yaroslav Y Marchenko; Anatolii V Dobrodumov; Anastasiya L Mikhrina; Marina G Martynova; Olga A Bystrova; Igor V Yakovenko; Alexander M Ischenko
Journal:  Int J Nanomedicine       Date:  2014-01-03

9.  Oligonucleotide aptamers: new tools for targeted cancer therapy.

Authors:  Hongguang Sun; Xun Zhu; Patrick Y Lu; Roberto R Rosato; Wen Tan; Youli Zu
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-05       Impact factor: 10.183

Review 10.  Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges.

Authors:  Jie Zhu; He Huang; Shiwu Dong; Liang Ge; Yuan Zhang
Journal:  Theranostics       Date:  2014-07-13       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.